996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Basic Info

  • Grade: Pharmaceutical Grade

    Factory Location: zhejiang

    Main Sales Markets: Asia,Africa

  • Monthly Production Capacity: 1t

    Contract Manufacturing: CRO,CMO

    Packaging Information: 1kg/Aluminum drum

  • Delivery Lead Time: 2-3Week

    Sample Provided: no

    Payment Terms: DP/DA/TT/LC

    Lovatinib is a multi-target tyrosine kinase inhibitor, which may act on a variety of cancers, so Eisai is still studying Lovatinib for other cancers, such as hepatocellular carcinoma, non-small cell lung cancer, melanoma, breast cancer, lymphoma, ovarian cancer, etc. There were 62 clinical studies related to lovatib chemicalbookil. In July 2017, Eisai submitted a marketing application for levatinib as a first-line treatment for advanced hepatocellular carcinoma to the US FDA and the European Medicines Agency. In clinical trials, levatinib was superior to sorafenib, the current standard treatment for advanced hepatocellular carcinoma.

Send your message to this supplier
  • From:
  • To:
    ZIBO WEIBIN IMP.& EXP.CO.,LTD
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service